AstraZeneca PLC's commercial teams are all set for the US launch of anifrolumab, the first medicine to be approved in over a decade for lupus, at the end of August, the company's biopharmaceuticals head has told Scrip.
Ruud Dobber said that the US Food and Drug Administration's approval of anifrolumab, which has the brand name Saphnelo, for the treatment of adults with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy, represents "a huge win, the first new treatment in more than 10 years for patients who don't have a lot of alternatives, and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?